CLDX (Celldex Therapeutics) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CLDX Celldex Therapeutics Inc CLDX
57 GF Score
Price $41.71
GF Value $2.66
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Celldex Therapeutics Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Celldex Therapeutics  (NAS:CLDX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Celldex Therapeutics Cyclically Adjusted PB Ratio Related Terms


Celldex Therapeutics Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Celldex Therapeutics's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celldex Therapeutics Cyclically Adjusted PB Ratio Chart

Celldex Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.34 1.57 1.59 1.19 1.71

Celldex Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.10 1.50 1.71 2.11 0.00

CLDX vs IRON, QURE, ATAI: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Celldex Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celldex Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celldex Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Celldex Therapeutics's Cyclically Adjusted PB Ratio falls into.


CLDX
57GF Score
Celldex Therapeutics Inc CLDX
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celldex Therapeutics Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Celldex Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Celldex Therapeutics's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=9.18/333.9520*333.9520
=9.180

Current CPI (Jun. 2026) = 333.9520.

Celldex Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201609 32.162 241.428 44.488
201612 33.038 241.432 45.699
201703 29.939 243.801 41.010
201706 27.249 244.955 37.149
201709 24.884 246.819 33.669
201712 25.595 246.524 34.672
201803 14.028 249.554 18.772
201806 12.262 251.989 16.250
201809 11.402 252.439 15.084
201812 10.375 251.233 13.791
201903 8.773 254.202 11.525
201906 7.399 256.143 9.647
201909 6.374 256.759 8.290
201912 5.540 256.974 7.200
202003 4.721 258.115 6.108
202006 6.099 257.797 7.901
202009 5.813 260.280 7.458
202012 5.286 260.474 6.777
202103 4.901 264.877 6.179
202106 4.601 271.696 5.655
202109 9.359 274.310 11.394
202112 8.977 278.802 10.753
202203 8.515 287.504 9.891
202206 7.807 296.311 8.799
202209 7.334 296.808 8.252
202212 6.911 296.797 7.776
202303 6.408 301.836 7.090
202306 5.873 305.109 6.428
202309 5.220 307.789 5.664
202312 7.680 306.746 8.361
202403 12.723 312.332 13.604
202406 12.276 314.175 13.049
202409 11.846 315.301 12.547
202412 11.254 315.605 11.908
202503 10.590 319.799 11.059
202506 9.871 322.561 10.220
202509 9.005 324.800 9.259
202512 7.921 324.054 8.163
202603 6.853 330.213 6.931
202606 9.180 333.952 9.180

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Celldex Therapeutics (CLDX) Overvalued in 2026?

Based on GuruFocus' analysis, Celldex Therapeutics stock appears to be overvalued. The current stock price of $41.71 is trading 1468% above its estimated GF Value™ of $2.66. GuruFocus considers Celldex Therapeutics to be Significantly Overvalued.

Key valuation signals for CLDX:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: $2.66 vs. price of $41.71 (1468% above fair value)
  • GF Score™: 57/100 with 8 warning signs

No single metric tells the full story. See the CLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celldex Therapeutics Business Description

Other Exchanges TCE2:Germany
Address 53 Frontage Road, Suite 220, Perryville III Building, Hampton, NJ, USA, 08827
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
57GF Score

Get the complete analysis for CLDX

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.71
Price
$2.66
GF Value